Tuberculosis (TB) has recently surpassed HIV as the primary infectious disease killer
worldwide, but the two diseases continue to display lethal synergy. The burden of TB is …

Introduction Contrasting findings have been published regarding the effect of human
immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). Objectives …

Background. The role of drug concentrations in clinical outcomes in children with
tuberculosis is unclear. Target concentrations for dose optimization are unknown. Methods …

Introduction Management of concomitant use of ART and TB drugs is difficult because of the
many drug–drug interactions (DDIs) between the medications. This systematic review …

Background Patients affected by poverty-related infectious diseases (PRDs) are
disproportionally affected by malnutrition. To optimize treatment of patients affected by …

Levofloxacin is increasingly used in the treatment of multidrug-resistant tuberculosis (MDR-
TB). There are limited pediatric pharmacokinetic data to inform dose selection for children …

Background: Therapeutic drug monitoring is useful in the treatment of tuberculosis to assure
adequate exposure, minimize antibiotic resistance, and reduce toxicity. Salivary therapeutic …

Background Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB)
treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young …

Although human immunodeficiency virus (HIV) coinfection is the most important risk factor
for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of …

HIV and tuberculosis (TB) often occur together with each exacerbating the other.
Improvements in vertical transmission prevention has reduced the number of HIV-infected …